论文部分内容阅读
目的:探讨布地奈德与可必特联合雾化吸入治疗重症哮喘的疗效。方法:选择重症哮喘患者57例,分为3组,每组19例。联合组(A组)给予布地奈德混悬液2ml、可必特2.5ml喷射雾化吸入;可必特组(B组)给予可必特2.5ml喷射雾化吸入;对照组(C组)不使用任何吸入剂。结果:治疗后3组患者动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、第1秒钟用力呼气容积(FEV1)、用力肺活量(FVC)均差异有统计学意义(均P<0.05);治疗后A组、B组各项观察指标与C组比较,均差异有统计学意义(均P<0.05)。结论:联合雾化吸入布地奈德与可必特能更好地改善重症哮喘患者的气流受限,且无明显不良反应。
Objective: To investigate the curative effect of budesonide and beide special combined inhalation on severe asthma. Methods: Fifty-seven patients with severe asthma were selected and divided into three groups with 19 cases in each group. Combination group (group A) given budesonide suspension 2ml, may be necessary 2.5ml spray atomization inhalation; may be special group (group B) to be given special 2.5ml jet atomized inhalation; control group (group C) Do not use any inhalant. Results: PaO2, PaCO2, FEV1, FVC in the three groups after treatment were significantly different (both P <0.05). After treatment, the observed indexes in group A and group B were significantly different from those in group C (all P <0.05). CONCLUSIONS: Combined inhalation of budesonide and beopic may improve airflow limitation in critically ill asthmatic patients with no apparent adverse effects.